Wobe-Mugos is a combination of proteolytic enzymes comprised of papain (100 mg), trypsin (40 mg), and chymotrypsin (40 mg). Proteolytic enzymes break down proteins throughout the body for various metabolic processes and can act as anti-inflammatory agents. This product has been evaluated as an intervention for mucositis and radiodermatitis in patients with cancer.
Research Evidence Summaries
Dorr, W., & Herrmann, T. (2007). Efficacy of Wobe-Mugos E for reduction of oral mucositis after radiotherapy: Results of a prospective, randomized, placebo-controlled, triple-blind phase III multicenter study. Strahlentherapie und Onkologie, 183(3), 121–127.
Intervention Characteristics/Basic Study Process:
Proteolytic enzymes comprised of papain (100 mg), trypsin (40 mg), and chymotrypsin (40 mg) were administered orally 3 x 4 tablets per day.
The study reported on 69 patients with tumors of the oropharynx or oral cavity undergoing a radiation dose higher than 40 Gy.
The study was conducted at a multicenter site from June 1996 to May 2000.
This was a prospective, randomized, triple-blind, placebo-controlled, parallel group study.
- Maximum grade of mucositis was recorded.
- The Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) toxicity criteria were used.
No statistically significant difference was found in analysis. Treatment with Wobe-Mugos E resulted in an earlier onset of mucositis and increased average scores for treatment duration.
The sample was not sufficient according to power analysis.